Exosome Characterization & Quality Analytics
OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs
Overview
At Creative BioMart Microbe, we provide comprehensive exosome characterization and quality analytics services tailored specifically for microbial extracellular vesicles (mEVs), including bacterial outer membrane vesicles (OMVs), Gram-positive membrane vesicles (MVs), probiotic-derived EVs, fungal/yeast EVs, and phage-derived vesicles. Our platform is built on MISEV2023 and ISEV best-practice guidelines, delivering critical quality attributes (CQAs) that support clients from early discovery through process development, CMC documentation, and regulatory filing. Unlike generic mammalian EV service providers, we have optimized every protocol for microbial membrane compositions—quantifying LPS, outer membrane proteins (OMP), and lipoteichoic acids (LTA) with validated assays that reflect the true biophysical and biochemical identity of microbial exosomes.
Figure 1. Schematic overview of the tiered exosome characterization and quality analytics workflow.
Creative BioMart Microbe offers end-to-end microbial exosome analytics, from sample receipt to validated data delivery. Explore the full Microbial Exosome Services ecosystem to see how characterization integrates with upstream production and downstream functional validation. Contact us for a custom quote and project consultation.
Services
Service Workflow
Service Details
Physical & Particle Profiling
This service establishes the physicochemical identity of microbial exosome preparations. NTA quantifies particle concentration and size distribution, while TEM and Cryo–EM resolve morphology and membrane integrity. DLS measures polydispersity index for homogeneity, and Zeta Potential analysis quantifies surface charge to predict colloidal stability.
Biochemical Marker & Composition Analysis
Microbial-specific markers (OmpA/C/F, LPS for Gram-negative; LTA, peptidoglycan for Gram-positive; β-1,3-glucan for fungal) are quantified by Western Blot, ELISA, and nanoflow cytometry. Lipidomic (PE, cardiolipin) and proteomic fingerprinting corroborate identity. Purity is assessed by membrane-integrity assays, fluorescent nanoflow cytometry, and negative-marker screening (L7/L12, GAPDH, HU for bacteria; Sec61α, enolase for fungi). Protein and lipid content are measured.
Multi-Omics Cargo Profiling
This service uncovers the complete molecular payload. sRNA-seq and miRNA profiling (qPCR or NGS) identify regulatory RNAs. LC-MS/MS proteomics via MASCOT and Scaffold delivers protein identification and quantification. Lipidomics and metabolomics complete the fingerprint. All projects include bioinformatics analysis—differential expression, pathway enrichment, and visualization—delivered as a standalone report.
Functional Potency & Bioactivity Assessment
For therapeutic or functional applications, this service bridges characterization to biological relevance. We measure cellular uptake by fluorescence microscopy and flow cytometry. Immunomodulatory potency is quantified via T-cell proliferation inhibition, macrophage polarization, and cytokine profiling. Target-specific enzymatic, angiogenic, and cell-migration effects are assessed per mechanism of action. For mechanism-driven biological validation, our companion Functional Validation & Mechanism of Action Studies bridge analytical CQAs to therapeutic relevance.
Service Specifications & QC Standards
Analytical Capability
- Our platform covers physical profiling (NTA, TEM, Cryo-EM, DLS, Zeta Potential), biochemical validation (WB, capillary Western, nanoflow cytometry, OMP/LPS/LTA quantification), multi-omics (sRNA-seq, proteomics, lipidomics, metabolomics), and functional bioactivity assays. Each method is validated with positive and negative controls, and instrument calibration is performed per batch.
Typical Data Range
- Particle size: 20–300 nm (mode ~50–150 nm for bacterial OMVs; fungal EVs occasionally extend to ~500 nm)
- Particle concentration: 1×108 – 1×1011 particles/mL (sample dependent; corresponds to 1×1011 – 1×1014 particles/L of culture before concentration)
- Purity (particle-to-protein ratio): >3×1010 particles/μg protein for high-purity grade; ≥2×109 particles/μg protein for routine research-grade preparations
- Zeta potential: –30 to –10 mV
- Membrane integrity: >70% lipid-bound particles (by fluorescent NTA)
Turnaround Time
| Project Type |
Timeline |
| Physical profiling package |
2–3 weeks |
| Biochemical analysis package |
2–4 weeks |
| Multi-omics package |
4–6 weeks |
| Full characterization bundle |
6–8 weeks |
| Expedited analysis |
Custom quote |
Timeline may vary based on sample complexity and assay customization.
Deliverables
- Raw data files (NTA video files, MS raw data, sequencing FASTQ)
- Processed analytical report with charts and statistical analysis
- Certificate of Analysis (CoA)
- Methodology summary and instrument calibration records
- Bioinformatics analysis report for multi-omics projects (pathway enrichment and visualization)
Quality Control
- Batch-level instrument calibration with positive and negative controls
- Inter-batch consistency assessment (NTA particle concentration CV <15%; size distribution CV <10%)
- MISEV2023 compliance checklist
- Contaminant screening for cell debris, protein aggregates, and residual media
- Optional CQA documentation package for IND-enabling studies
All CQA data packages are designed to support release testing for Application-Grade Manufacturing and Formulation & Stability scale-up programs.
Sample Requirements
| Required Information |
Optional Information |
Not Accepted |
- Sample type (bacterial culture supernatant, OMV purified fraction, phage preparation, yeast EV)
- Estimated particle concentration or total protein yield
- Strain background and culture conditions
- Sample volume (≥500 μL recommended)
|
- Prior isolation and purification method (TFF, SEC, ultrafiltration, etc.)
- Target application (research, CMC, regulatory filing)
- Special assay requests (fluorescent NTA, functional potency)
- Control sample requirements
|
- Samples subjected to more than three freeze-thaw cycles
- Samples with unidentified strain origin or undocumented culture conditions
- Severely degraded, contaminated, or detergent-heavy preparations
- Samples preserved with fixatives or antimicrobial agents
|
Note: For projects requiring upstream strain construction and bioreactor optimization prior to analytical characterization, explore our Exosome-Producing Strain Engineering & Fermentation Optimization service for integrated handoff.
Our Advantages
- Microbial EV Specialization: Deep expertise in bacterial OMVs and phage-derived vesicles, with analytical protocols optimized for microbial membrane compositions rather than generic mammalian EV templates.
- Rapid Turnaround: Standard physicochemical packages are delivered in 2–3 weeks and multi-omics projects in 4–6 weeks, with milestone updates at every QC checkpoint.
- Flexible Service Packages: Tiered service options scale seamlessly from discovery screening to GMP-grade QC without vendor switching or method re-validation.
- Integrated Production-Analytics Loop: Seamless handoff from upstream strain engineering and fermentation optimization to downstream characterization ensures full traceability and consistent batch quality.
- Regulatory-Ready Documentation: Comprehensive CoA, method summaries, and optional CQA documentation packages suitable for IND-enabling studies, cosmetic raw material registration, and food-grade safety filings.
Applications
Biomarker Discovery & Liquid Biopsy Development
Multi-omics profiling of microbial exosomal cargo identifies disease-associated RNA and protein signatures for preclinical biomarker validation and companion diagnostic development.
Therapeutic EV Process Development & CMC Support
Batch-to-batch CQA monitoring and regulatory-ready data packages that accelerate therapeutic EV transition from preclinical development to clinical manufacturing.
Probiotic, Cosmetic & Food-Grade Raw Material QC
Functional potency validation for probiotics, safety profiling for cosmetics, and gastrointestinal stability assessment for food-grade mEV raw materials.
Vaccine Adjuvant & Drug Delivery Carrier Characterization
OMV-based vaccine adjuvant qualification and drug carrier assessment for loading efficiency, release kinetics, and target-cell uptake validation.
Case Study
Case Study 1: NTA-Based Characterization of Oxalobacter formigenes Extracellular Vesicles
This study reported the first confirmation of EV production by the Gram-negative gut commensal Oxalobacter formigenes. EVs were isolated from culture supernatant by affinity chromatography and characterized by nanoparticle tracking analysis (NTA) using the NanoSight NS300. NTA confirmed a mean vesicle diameter of 122.9 ± 46.3 nm, with D10 = 80.4 nm, D50 = 111.5 nm, and D90 = 182.6 nm—consistent with established bacterial EV size ranges. This study demonstrates how NTA serves as a robust, quantitative tool for EV identity verification, yielding critical quality attributes including particle concentration, size distribution, and polydispersity metrics essential for downstream metabolomic and functional studies.
Figure 2. NTA confirmation of O. formigenes EVs. (Chamberlain, et al., 2021)
Case Study 2: Size-Resolved Airborne Microbiome Profiling Distinguishes Bacterial EVs from Whole Cells
This study demonstrated a novel size-resolved approach to characterize indoor airborne bacterial communities by separating micro-sized airborne bacteria (m-AB) from nano-sized airborne bacterial extracellular vesicles (n-ABE). Using 16S rDNA amplicon sequencing, they profiled phylum-, genus-, and species-level composition of both fractions before and after scented candle burning. Pre-burning n-ABE was dominated by Pseudomonas, Lactobacillus, and Ralstonia, while post-burning Phyllobacterium myrsinacearum EVs increased dramatically—marking the first detection of this species in indoor air. This study illustrates how size-based fractionation coupled with molecular profiling can distinguish EV-associated DNA signatures from whole-cell contaminants, yielding critical quality attributes for environmental and clinical EV analytics.
Figure 3. Size-resolved airborne microbiome composition. (Yun, et al., 2025)
FAQs
Q: What types of microbial exosomes can be characterized?
A: We characterize bacterial outer membrane vesicles (OMVs), Gram-positive membrane vesicles (MVs), probiotic-derived EVs, fungal/yeast EVs, phage-derived vesicles, and other microbial EV preparations.
Q: How much sample volume is required for a full characterization package?
A: The physical and biochemical package requires a minimum of 500 μL. Multi-omics projects are best supported with at least 1 mL or 100 μg total protein. Low-input custom protocols are available upon consultation.
Q: What is the difference between standard NTA and fluorescent NTA?
A: Standard NTA detects all particles indiscriminately. Fluorescent NTA (fl-NTA) uses membrane-specific dyes to count only intact lipid-bilayer-enclosed vesicles, excluding protein aggregates and non-vesicular impurities for a truer purity assessment.
Q: Can you perform batch-to-batch consistency analysis for GMP-grade EV manufacturing?
A: Yes. We provide statistical comparison of particle size, concentration, marker expression, and purity across manufacturing batches, together with CQA trending analysis for release documentation.
Q: Do you provide bioinformatics support for multi-omics data?
A: Yes. Every multi-omics project includes differential expression analysis, pathway enrichment, biomarker prioritization, and interactive visualization delivered as a standalone interpretive report.
Q: What quality standards do you follow for microbial EV characterization?
A: All protocols are designed in alignment with MISEV2023 guidelines and ISEV best practices. We can adapt documentation to meet FDA, EMA, or regional cosmetic and food-safety regulatory requirements.
Q: How should samples be shipped to ensure stability?
A: Ship frozen at –80°C on dry ice. Avoid repeated freeze-thaw cycles. We provide a detailed shipping guideline and perform incoming quality inspection upon receipt.
Q: Can functional potency testing be added to a standard characterization package?
A: Yes. Cellular uptake, immunomodulation, enzymatic activity, and other functional modules can be integrated as upgrade options into any standard package.
References:
- Chamberlain, C. A., et al. (2021). Extracellular vesicle analysis by paper spray ionization mass spectrometry. Metabolites, 11(5), 308.
- Yun, H., et al. (2025). Impact of scented candle use on indoor air quality and airborne microbiome. Scientific Reports, 15(1), 10181.
